Skip to main content

Uncomplicated Urinary Tract Infections

1
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK3882347Phase 1
Iterum Therapeutics
Iterum TherapeuticsDUBLIN 1, Ireland
1 program
Sulopenem-Etzadroxil/ProbenecidPHASE_31 trial
Active Trials
NCT03354598Completed1,671Est. Jan 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Iterum TherapeuticsSulopenem-Etzadroxil/Probenecid

Clinical Trials (1)

Total enrollment: 1,671 patients across 1 trials

NCT03354598Iterum TherapeuticsSulopenem-Etzadroxil/Probenecid

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Start: Aug 2018Est. completion: Jan 20201,671 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.